Search
Chronic Lymphocytic Leukemia Clinical Trials
A listing of 77 Chronic Lymphocytic Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 77
There are currently 77 active clinical trials seeking participants for Chronic Lymphocytic Leukemia research studies. The states with the highest number of trials for Chronic Lymphocytic Leukemia participants are California, Ohio, Michigan and Illinois.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Recruiting
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorectal cancer and blood cancers fresh NK cells from a healthy donor has recently been discovered. The purpose of this study is to show that using two medicines (vactosertib and IL-2) with NK cells will be safe and will activate the donor NK cells. NK cell... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Recruiting
This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block the activation of certain cells that lead to the growth of cancerous B cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer ce... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Recruiting
This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/27/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Recruiting
The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).
Gender:
All
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Recruiting
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate.
Cohort A: Participants with relapsed or refractory MCL rel... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +105 locations
Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Recruiting
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +582 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of nemtabrutinib compared to investigator's choice of fludarabine plus cyclophosphamide plus rituximab (FCR) or bendamustine plus rituximab (BR) in participants with previously untreated CLL/SLL without 17p deletion and/or tumor protein (TP) 53 mutation. The primary hypothesis is that nemtabrutinib is superior to FCR/BR with respect to progression-free survival (PFS).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Highlands Oncology Group ( Site 5205), Springdale, Arkansas +89 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Recruiting
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent centra... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: USA Mitchell Cancer Institute ( Site 0014), Mobile, Alabama +60 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL
Recruiting
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University Of California LA UCLA Hematology Oncology, Los Angeles, California +40 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are:
Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant?
Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: City of Hope, Duarte, California +16 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Recruiting
To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/10/2024
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Recruiting
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Octapharma Research Site, Saint Petersburg, Florida +82 locations
Conditions: Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
1 - 12 of 77